GLP1R and metabolic dysfunction-associated steatohepatitis: The LEAN phase 2 trial [227] reported, in patients with biopsy-confirmed MASH, histological resolution of MASH with liraglutide, another GLP-1 agonist, given at a dose of 1.8 mg daily compared to placebo.